TP53 and B-cell chronic lymphocytic leukemia: Non-disruptive TP53 mutations with potential gain of function have been associated with poor outcomes in multiple tumor types such as squamous cell carcinomas of the head and neck [18], chronic lymphocytic leukemia [19] and metastatic lung cancer [20].